IRWD

+ Watchlist + Portfolio

Ironwood Pharmaceuticals, Inc.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $4.36
52-Week Range: $1.01 – $5.78
Market Cap: $684.09M
P/E (TTM): 5.24
EPS (TTM): 0.79
Dividend Yield: —

Advanced Metrics

Price/Book: —
PEG Ratio: —
Return on Equity: —
Return on Assets: 47.02%
Gross Margin: 77.22%
Operating Margin: 70.16%
Profit Margin: 33.36%
Current Ratio: 6.06
Debt/Equity: —
Total Debt: $396.87M
Free Cash Flow: $121.83M
Revenue Growth: 32.60%
Earnings Growth: 125.70%
Enterprise Value: $1.00B

IRWD Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$410.60M	$442.74M	$351.41M	$296.15M
Cost of Revenue	$0.00	—	—	—
Gross Profit	$410.60M	—	—	—
Research & Development	$44.27M	$116.08M	$111.42M	$95.14M
Selling, General & Admin	$115.99M	$158.31M	$144.27M	$82.26M
Operating Expenses	$160.26M	$274.40M	$255.69M	$177.39M
Operating Income	$250.34M	$168.34M	$95.72M	$118.76M
EBITDA	$261.44M	-$924.87M	$100.24M	$104.65M
Pretax Income	$252.42M	-$948.07M	$65.20M	$70.03M
Income Tax	$77.36M	$83.49M	$64.32M	$46.01M
Net Income	$175.06M	-$1.00B	$880.00K	$24.02M
Diluted EPS	0.96	-6.45	0.01	0.15
Diluted Shares	186.31M	155.44M	160.08M	162.98M

IRWD Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$656.20M	$92.15M	$88.56M	$215.46M
Receivables	$115.46M	$129.12M	$81.89M	$46.74M
Current Assets	$780.63M	$233.29M	$182.37M	$274.18M
Total Assets	$1.10B	$471.07M	$350.91M	$396.90M
Current Liabilities	$25.52M	$276.10M	$38.85M	$242.22M
Long-Term Debt	$396.25M	$498.31M	$583.99M	$385.00M
Total Debt	$415.92M	$715.54M	$599.48M	$597.80M
Total Liabilities	$448.14M	$817.37M	$652.24M	$658.74M
Retained Earnings	-$696.38M	-$1.70B	-$1.70B	-$1.67B
Shareholders' Equity	$652.38M	-$346.30M	-$301.33M	-$261.83M
Working Capital	$755.10M	-$42.81M	$143.52M	$31.96M
Net Debt	—	$605.72M	$495.43M	$369.22M

IRWD Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	$273.76M	$183.43M	$103.55M	$127.04M
Capital Expenditure	-$136.00K	-$273.00K	-$142.00K	-$34.00K
Free Cash Flow	$273.63M	$183.15M	$103.41M	$127.01M
Depreciation & Amortisation	$1.42M	$1.57M	$2.01M	$1.88M
Stock-Based Compensation	$27.05M	$32.01M	$29.85M	$17.25M
Investing Cash Flow	-$136.00K	-$1.03B	-$142.00K	-$34.00K
Financing Cash Flow	-$237.55M	$277.16M	-$106.97M	$216.00K
Share Repurchases	-$126.39M	$0.00	$0.00	—
Net Change in Cash	$36.07M	-$565.73M	-$3.56M	$127.23M

IRWD Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Revenue	$41.14M	$85.24M	$122.06M	$47.71M	$106.51M
Research & Development	$27.43M	$23.37M	$22.47M	$21.86M	$21.94M
Selling, General & Admin	$24.26M	$16.80M	$21.91M	$19.29M	$12.03M
Operating Expenses	$51.69M	$40.17M	$44.38M	$41.16M	$33.97M
Operating Income	-$10.55M	$45.07M	$77.68M	$6.55M	$72.53M
EBITDA	-$27.89M	$46.65M	$76.93M	$8.80M	$74.58M
Pretax Income	-$36.27M	$37.82M	$68.02M	$455.00K	$65.17M
Income Tax	$1.11M	$14.22M	$27.94M	$2.73M	$24.40M
Net Income	-$37.39M	$23.60M	$40.08M	-$2.28M	$40.77M
Diluted EPS	-0.23	0.14	0.23	-0.01	0.24
Diluted Shares	162.55M	176.84M	177.76M	162.44M	169.89M

IRWD Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Cash & Equivalents	$108.48M	$92.85M	$140.41M	$215.46M	$220.47M
Receivables	$39.77M	$86.17M	$120.37M	$46.74M	$105.84M
Current Assets	$160.58M	$191.75M	$273.84M	$274.18M	$332.29M
Total Assets	$327.21M	$342.95M	$396.06M	$396.90M	$434.57M
Current Liabilities	$48.10M	$232.53M	$242.50M	$242.22M	$236.31M
Long-Term Debt	$584.16M	$385.00M	$385.00M	$385.00M	$385.00M
Total Debt	$599.08M	$598.67M	$598.24M	$597.80M	$597.36M
Total Liabilities	$661.27M	$651.11M	$660.22M	$658.74M	$651.71M
Retained Earnings	-$1.74B	-$1.71B	-$1.67B	-$1.67B	-$1.63B
Shareholders' Equity	-$334.05M	-$308.16M	-$264.16M	-$261.83M	-$217.14M
Working Capital	$112.48M	-$40.77M	$31.34M	$31.96M	$95.98M
Net Debt	$475.68M	$491.48M	$444.10M	$369.22M	$364.38M

IRWD Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Operating Cash Flow	$19.95M	-$15.07M	$47.58M	$74.58M	$5.12M
Capital Expenditure	-$31.00K	-$2.00K	-$2.00K	—	—
Free Cash Flow	$19.92M	-$15.07M	$47.58M	$74.58M	$5.12M
Depreciation & Amortisation	$479.00K	$467.00K	$475.00K	$460.00K	$443.00K
Stock-Based Compensation	$5.29M	$4.52M	$3.61M	$3.82M	$3.65M
Investing Cash Flow	-$31.00K	-$2.00K	-$2.00K	$1.00K	$0.00
Financing Cash Flow	$6.00K	$88.00K	$0.00	$122.00K	$0.00
Net Change in Cash	$19.93M	-$14.98M	$47.58M	$74.70M	$5.12M

Market Snapshot

About

Ironwood Pharmaceuticals is a commercial-stage biopharmaceutical company focused on gastrointestinal (GI) diseases. The company's lead product, LINZESS, is a leading prescription medication for adults suffering from irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC). Ironwood has built its business around developing and commercializing innovative therapies for GI disorders that significantly impact patients' quality of life. The company collaborates with partners to maximize the reach of its products globally. Ironwood continues to invest in research and development for additional GI and metabolic disorder treatments.